HLJ2 Effectively Ameliorates Colitis-Associated Cancer via Inhibition of NF-κB and Epithelial-Mesenchymal Transition

Huachen Song1, Xiaonan Tang1, Xiang Li1

  • 1State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, People's Republic of China.

Abstract

Insights

HLJ2 shows promise as a novel therapeutic for colitis-associated cancer (CAC). This compound inhibits key pathways like nuclear factor-κB and epithelial-mesenchymal transition, crucial for cancer progression and metastasis.

Area of Science:

  • Gastroenterology
  • Oncology
  • Molecular Biology

Background:

  • Colitis-associated cancer (CAC) is a significant cause of mortality in IBD patients.
  • Existing anti-CAC drugs have limitations in safety, specificity, and side effects.
  • Novel therapeutic candidates for CAC are urgently needed.

Purpose of the Study:

  • To investigate the therapeutic potential of HLJ2, a novel synthesized compound, for ameliorating CAC.
  • To elucidate the underlying mechanisms of HLJ2's action in CAC models.

Main Methods:

  • An in vivo AOM/DSS-induced CAC model was employed to assess HLJ2's efficacy.
  • Immunohistochemistry and Western blot analyses were used to evaluate pathological damage and molecular changes.
  • In vitro studies utilized TGF-β1-stimulated SW480 cells to examine HLJ2's effects on nuclear factor-κB (NF-κB) and epithelial-mesenchymal transition (EMT).

Main Results:

  • HLJ2 significantly inhibited pro-inflammatory cytokines and NF-κB in the AOM/DSS model.
  • The compound suppressed EMT and key metastasis-related proteins, including snail.
  • In vitro, HLJ2 demonstrated inhibition of NF-κB and EMT in TGF-β1-stimulated cells, consistent with in vivo findings.

Conclusions:

  • HLJ2 ameliorates CAC by inhibiting NF-κB and downstream EMT.
  • HLJ2 presents a potential therapeutic candidate for CAC with significant efficacy and minimal side effects.

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
719
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.1K
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
659
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.9K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
332
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.6K